Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients

Exclusion Criteria

• •Patients less than age of 18 years of age
• •Pregnant patients
• •Patients unable to provide written informed consent
• •Patients in whom there are contraindications to the administration of intravenous contrast material (as detailed in out Department of Radiology intravenous contrast material use guidelines), including renal contraindications (such as a University of Michigan laboratory record of most recent serum creatinine concentration of \>1.5 mg/dl or an estimated glomerular filtration rate (EGFR) \<60 ml/min); if no serum creatinine is available, patients will be receive contrast material based on departmental guidelines
• •Patients who are undergoing therapy with agents purported to reduce the risk of CIN (such as acetylcysteine, theophylline, or intravenous hydration)
• •Patients who are unable to provide the follow-up serum creatinine concentration measurements
• •Patients undergoing CT examinations that utilize a higher concentration of iodine (for example, 370 mg I/ml contrast material)
• •Patients who have experienced allergic-like reactions to contrast; including patients who receive corticosteroid/antihistamine premedication to reduce the risk of an acute allergic-like reaction
• •Patients who do not receive the study criterion for dose of contrast material; and patients in whom a contrast extravasation of more than 5 ml occurs (so that it is not possible to determine how much contrast material the patient received as a direct intravenous injection)
• •Patients participating in other investigational drug, contrast material, or device trials